Keywords: seattle, genetics, highlights, ab-drug, conjugate, programs, washington
Seattle Genetics highlights Ab-drug conjugate programs
Article | 03 November 2008
Washington, USA-based Seattle Genetics has announced data highlighting preclinical findings on two of its antibody-drug conjugate programs, SGN-35 and SGN-19 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
